Exhibit I - Unaudited Interim Financial Information

Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)

	September 30, 2026 (Unaudited)	December 31, 2025
Assets		
Current assets:		
Cash	$ 16,540	$ 27,434
Accounts receivable, net of allowance for credit losses of $135 and $118, respectively	769	439
Contract assets	873	275
Other current assets	836	672
Total current assets	**19,018**	**28,820**
Property, plant and equipment, net	193	128
Intangible assets, net	13	73
Finance lease right-of-use assets	9	11
Operating lease right-of-use assets	178	269
Goodwill	182	182
Other non-current assets	$ 72	$ 140
Total assets	**$ 19,665**	**$ 29,623**
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	$ 749	$ 1,113
Accrued payroll	316	774
Contract liabilities	225	150
Finance lease liabilities, current	3	3
Operating lease liabilities, current	136	125
Other current liabilities	390	101
Total current liabilities	**1,819**	**2,266**
Finance lease liabilities, net of current portion	6	9
Operating lease liabilities, net of current portion	48	152
Total liabilities	**1,873**	**2,427**
Commitments and Contingencies (Note 16)		
Stockholders' Equity		
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 57,726,850 and 57,542,113 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	6	6
Additional paid-in capital	62,244	59,456
Accumulated deficit	(44,719)	(32,503)
Accumulated other comprehensive income	261	237
Total stockholders' equity	**17,792**	**27,196**
Total liabilities and stockholders' equity	**$ 19,665**	**$ 29,623**

Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited) (in thousands, except share and per share data)

	Three Months Ended September 30.		Nine Months Ended September 30.	
	2026	2025	2026	2025
Revenue	$ 1,787	$ 1,683	$ 4,553	$ 4,837
Cost of services (exclusive of depreciation shown separately below)	(830)	(700)	(2,123)	(2,118)
Gross profit	**957**	**983**	**2,430**	**2,719**
Operating expenses:				
Selling, general and administrative expenses	4,326	2,493	9,912	5,701
Research and development	450	—	5,119	—
Depreciation and amortization expense	36	29	86	88
Total operating expenses	4,812	2,522	15,117	5,789
Loss from operations	**(3,855)**	**(1,539)**	**(12,687)**	**(3,070)**
Gain on insurance settlement	—	—	27	—
Other income	91	232	444	235
Net loss before income taxes	**(3,764)**	**(1,307)**	**(12,216)**	**(2,835)**
Provision for income taxes	—	—	—	1
Net loss	**$ (3,764)**	**$ (1,307)**	**$ (12,216)**	**$ (2,836)**
Other comprehensive income (loss):				
Foreign currency translation adjustments	(9)	160	24	120
Total other comprehensive income (loss)	(9)	**160**	24	**120**
Net loss and other comprehensive loss	**$ (3,773)**	**$ (1,147)**	**$ (12,192)**	**$ (2,716)**
Net loss per common share – basic and diluted	$ (0.07)	$ (0.02)	$ (0.21)	$ (0.06)
Weighted average common shares outstanding - basic and diluted	57,691,306	54,260,091	57,660,360	45,750,667

Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders' Equity
(Unaudited) (in thousands, except share and per share data)

	Common Stock		Preferred Stock Series A		Preferred Stock Series A Prime		Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive	Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount				
Balance, January 1, 2025	**773,941**	**$ —**	**655,351**	**$ —**	**115,057**	**$ —**	**$ 29,962**	**$ (27,167)**	**$ 122**	**$ 2,917**
Retroactive application of Merger	39,127,838	4	(655,351)	—	(115,057)	—	(4)	—	—	—
Adjusted Balance beginning of	39,901,779	$ 4	—	$ —	—	$ —	$ 29,958	$ (27,167)	$ 122	$ 2,917
Exercise of stock options	1,330,620	—	—	—	—	—	70	—	—	70
Stock based compensation	—	—	—	—	—	—	25	—	—	25
Foreign currency translation	—	—	—	—	—	—	—	—	(50)	(50)
Net loss	—	—	—	—	—	—	—	(166)	—	(166)
Balance, March 31, 2025	**41,232,399**	**4**	**—**	**—**	**—**	**—**	**30,053**	**(27,333)**	**72**	**2,796**
Exercise of stock options	2,737,355	—	—	—	—	—	324	—	—	324
Stock based compensation	—	—	—	—	—	—	30	—	—	30
Foreign currency translation	—	—	—	—	—	—	—	—	10	10
Net loss	—	—	—	—	—	—	—	(1,363)	—	(1,363)
Balance, June 30, 2025	**43,969,754**	**4**	**—**	**—**	**—**	**—**	**30,407**	**(28,696)**	**82**	**1,797**
Exercise of stock options	304,545	—	—	—	—	—	40	—	—	40
Stock based compensation	—	—	—	—	—	—	192	—	—	192
Shares issued in reverse acquisition	2,250,000	—	—	—	—	—	(176)	—	—	(176)
Treasury Stock	(26,870)	—	—	—	—	—	(81)	—	—	(81)
Shares issued in private placement offering, net of offering costs	11,012,387	1	—	—	—	—	28,847	—	—	28,848
Foreign currency translation	—	—	—	—	—	—	—	—	160	160
Net loss	—	—	—	—	—	—	—	(1,307)	—	(1,307)
Balance, September 30, 2025	**57,509,816**	**$5**	**—**	**$ —**	**—**	**$ —**	**$ 59,229**	**$ (30,003)**	**$ 242**	**$ 29,473**

Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders' Equity
(Unaudited) (in thousands, except share and per share data)

	Common Stock		Preferred Stock Series A		Preferred Stock Series A Prime		Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive	Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount				
Balance, January 1, 2026	**57,542,113**	**$ 6**	**—**	**$ —**	**—**	**$ —**	**$ 59,456**	**$ (32,503)**	**$ 237**	**$ 27,196**
Exercise of stock options and distribution of restricted stock units	105,500	—	—	—	—	—	4	—	—	4
Stock based compensation	—	—	—	—	—	—	522	—	—	522
Foreign currency translation adjustments	—	—	—	—	—	—	—	—	48	48
Net loss	—	—	—	—	—	—	—	(5,416)	—	(5,416)
Balance, March 31, 2026	**57,647,613**	**6**	**—**	**—**	**—**	**—**	**59,982**	**(37,919)**	**285**	**$ 22,354**
Exercise of stock options and distribution of restricted stock units	19,500	—	—	—	—	—	—	—	—	—
Stock based compensation	—	—	—	—	—	—	363	—	—	363
Foreign currency translation adjustments	—	—	—	—	—	—	—	—	(15)	(15)
Net loss	—	—	—	—	—	—	—	(3,036)	—	(3,036)
Balance, June 30, 2026	**57,667,113**	**6**	**—**	**—**	**—**	**—**	**60,345**	**(40,955)**	**270**	**19,666**
Exercise of stock options and distribution of restricted stock units	59,737	—	—	—	—	—	11	—	—	11
Stock based compensation	—	—	—	—	—	—	1,888	—	—	1,888
Foreign currency translation	—	—	—	—	—	—	—	—	(9)	(9)
Net loss	—	—	—	—	—	—	—	(3,764)	—	(3,764)
Balance, September 30, 2026	**57,726,850**	**$ 6**	**—**	**$ —**	**—**	**$ —**	**$ 62,244**	**$ (44,719)**	**$ 261**	**$ 17,792**

Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited) (in thousands, except share and per share data

	Nine Months Ended September 30,	
	2026	**2025**
Cash Flows from Operating Activities:		
Net loss	$ (12,216)	$ (2,836)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization expense	86	88
Interest expense	1	1
Stock based compensation	2,773	247
Gain on debt extinguishment	—	(74)
Gain on insurance settlement	(27)	—
Changes in operating assets and liabilities:		
Accounts receivable	(347)	(499)
Allowance for credit losses	17	(17)
Contract assets	(598)	(30)
Other current assets	(164)	(968)
Other non current assets	68	—
Accounts payable	(364)	605
Contract liabilities	75	414
Accrued expenses	(458)	(174)
Other current liabilities	289	16
Operating lease right-of-use assets and lease liabilities	(3)	(3)
Net cash used in operating activities	**(10,868)**	**(3,230)**
Cash Flows from Investing Activities:		
Purchases of property, plant and equipment	(89)	(38)
Proceeds from insurance on disposal of fixed asset	27	—
Cash acquired in reverse acquisition	—	7
Net cash used in investing activities	**(62)**	**(31)**
Cash Flows from Financing Activities:		
Payment of finance lease liability	(3)	—
Proceeds from issuance of Series A Prime Preferred Stock	-	—
Proceeds from Offering, net of Offering costs	—	28,848
Payment of share repurchase liability	—	(81)
Proceeds from exercise of stock options	15	434
Net cash provided by financing activities	**12**	**29,201**
Net change in cash and cash equivalents	**(10,918)**	**25,940**
Effect of exchange rate on cash and cash equivalents	24	120
Cash and cash equivalents:		
Beginning of period	27,434	2,149
End of period	**$ 16,540**	**$ 28,209**
Supplemental schedule of non-cash investing and financing activities:		
Issuance of common stock in reverse acquisition	$ —	$ 176